Trials / Completed
CompletedNCT02614261
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,117 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galcanezumab | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2015-11-30
- Primary completion
- 2017-03-16
- Completion
- 2021-07-14
- First posted
- 2015-11-25
- Last updated
- 2022-05-18
- Results posted
- 2019-01-07
Locations
117 sites across 13 countries: United States, Argentina, Canada, Czechia, Germany, Israel, Italy, Mexico, Netherlands, Puerto Rico, Spain, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT02614261. Inclusion in this directory is not an endorsement.